Requiring health insurance policies to provide coverage for preexposure prophylaxis HIV medication.
Summary
SB935, titled the PrEP for Pennsylvania Act, would require most health insurance policies issued, renewed, extended, or modified in Pennsylvania to cover the cost of FDA-approved preexposure prophylaxis (PrEP) HIV medication. The mandate applies to individual and group health insurance policies regulated under Pennsylvania insurance laws, including HMOs and certain nonprofit health plans, but excludes several limited or specialized coverage types such as accident-only, dental, vision, Medicare supplement, workers’ compensation, and automobile medical payment insurance.
The bill also places limits on how insurers may manage coverage for PrEP. It prohibits an insurance provider from moving PrEP medications into a specialty tier solely for monetary gain, and it bars policies from requiring counseling by an infectious disease specialist or immunologist as a condition of access unless such counseling is medically necessary. The effective date would be 60 days after enactment.
Impact
If enacted, SB935 would amend the practical coverage obligations of Pennsylvania health insurers by creating a new mandated benefit for PrEP HIV medication. It would affect insurers, health maintenance organizations, hospital and professional health service plans, and policyholders covered under the specified insurance statutes by requiring payment for the medication and restricting certain utilization-management practices. The bill would not apply to several exempt insurance products, so its legal effect would be concentrated in standard medical coverage markets rather than supplemental or limited-benefit plans.
Sentiment
Based on the bill’s sponsorship and the absence of recorded committee debate or votes in the provided materials, the available context suggests the bill is being advanced as a public health and HIV prevention measure. The sponsor list indicates support from multiple Democratic senators, which is consistent with a generally favorable posture toward expanding access to preventive medication. No contrary testimony, amendments, or recorded opposition are included in the materials provided.
Contention
The main points of potential contention are likely to be cost and insurer control over formularies and utilization management. Insurers may object to a mandatory coverage requirement for a branded or specialized preventive medication and to the restriction on placing PrEP in a specialty tier, which could limit pricing flexibility. Another possible issue is the prohibition on requiring specialist counseling, which some may view as limiting clinical gatekeeping, while supporters are likely to argue that these provisions prevent unnecessary barriers to HIV prevention and improve access for patients at risk.
Requiring health insurance policies to provide coverage for pre-exposure prophylaxis and post-exposure prophylaxis HIV medication and associated laboratory tests and patient visits.
In casualty insurance, further providing for conditions subject to which policies are to be issued and for health insurance coverage for certain children of insured parents.
In casualty insurance, further providing for conditions subject to which policies are to be issued and for health insurance coverage for certain children of insured parents.
Prohibiting discriminatory practices against applicants and enrollees under certain insurance policies based on claims or prescriptions involving prophylaxis HIV medication.
Providing for patient access to diagnostics and treatments for Lyme disease and related tick-borne illnesses; and requiring health care policies to provide certain coverage.
Providing for health care insurance coverage protections; imposing duties on the Insurance Department and the Insurance Commissioner; and imposing penalties.